IP Library › Granted Patent US 12,471,579
Granted Patent B2
US 12,471,579 · App. 18/159,414 · Granted Nov 18, 2025

Mouse model of DITRA disease and uses thereof

Inventors: Andrew J. Murphy (Croton-on-Hudson, NY); Alexander O. Mujica (Elmsford, NY); Ka-Man Venus Lai (Seattle, WA); Sokol Haxhinasto (Brookfield, CT); Zaruhi Hovhannisyan (Hoboken, NJ)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278C07K16/244C07K16/2866C12N15/8509A01K2207/15A01K2217/072A01K2217/15A01K2227/105A01K2267/0368C07K2317/24C07K2317/76C12N2015/8527
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,471,579
App. No.
18/159,414
Granted
Nov 18, 2025
Kind
B2
Abstract

This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36α, β and γ ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.

Claims (17)

1 . A method of determining whether a compound is capable of inhibiting colon inflammation, the method comprising

a) inducing colon inflammation in a first mouse and a second mouse, both of which comprise in the genome:

(1) a humanized interleukin-1 receptor-like 2 (Il1r12) gene, wherein the humanized Il1r12 gene

(i) encodes a humanized Il1rl2 protein that comprises the ectodomain of a human ILIRL2 protein and the transmembrane-cytoplasmic domains of a mouse Il 1r12 protein;

(ii) results from a replacement of a genomic fragment of an endogenous mouse Il1r12 gene encoding the ectodomain of an endogenous mouse Il1rl2 protein with a nucleotide sequence of a human ILIRL2 gene encoding the ectodomain of the human IL 1RL2 protein; and

(iii) is operably linked to the endogenous mouse Il 1rl2 promoter;

(2) a human interleukin-1 family member 6 (IL1F6) gene which replaces the endogenous mouse Il1f6 gene;

(3) a human interleukin-1 family member 8 (IL1F8) gene which replaces the endogenous mouse Il1f8 gene; and

(4) a human interleukin-1 family member 9 (IL1F9) gene which replaces the endogenous mouse Il1f9 gene;

wherein the mice are homozygous for the humanized Il1r12 gene, human ILIF6 gene, human IL1F8 gene and human ILIF9 gene, and wherein the mice express the humanized Il1r12 protein, human IL1F6, human IL1F8, and human IL1F9;

b) administering the compound to the first mouse but not the second mouse; and

c) evaluating colon inflammation in the first mouse and second mouse obtained in step b), wherein decreased inflammation in the colon of the first mouse as compared to the second mouse indicates that the compound inhibits colon inflammation.

2 . The method of claim 1 , wherein the humanized Il1r12 protein comprises the amino acid sequence as set forth in SEQ ID NO: 7.

3 . The method of claim 1 , wherein the humanized Il 1r12 gene comprises exons 1-2 of the endogenous mouse Il1rl2 gene, exons 3-8 of the human ILIRL2gene, and exons 9-11 of the endogenous mouse Il1r12 gene.

4 . The method of claim 1 , wherein said evaluating inflammation is performed by evaluating colon length in the first mouse and the second mouse obtained in step b), wherein an increase in colon length of at least 15% in the first mouse as compared to the second mouse indicates that the compound inhibits colon inflammation.

5 . The method of claim 1 , wherein said evaluating inflammation is performed by measuring the level of Myeloperoxidase (MPO) activity in colon homogenates of the first mouse and the second mouse obtained in step b), wherein a decrease in the level of MPO of at least 20% in the first mouse as compared to the second mouse indicates that the compound inhibits colon inflammation.

6 . The method of claim 1 , wherein said evaluating inflammation is performed by measuring the level of a cytokine in colon homogenates of the first mouse and the second mouse obtained in step b), wherein the cytokine is KC-GRO, IL-6, IL-1β, TNFa, or IL-4, wherein a decrease in the level of the cytokine of at least 50% in the first mouse as compared to the second mouse indicates that the compound inhibits colon inflammation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2025
From: MURPHY, ANDREW J.; MUJICA, ALEXANDER O.; LAI, KA-MAN VENUS; HAXHINASTO, SOKOL; HOVHANNISYAN, ZARUHI
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 071936/0445 →
Continuity (4)
Continuation 16512949 · Jul 16, 2019
Provisional Application 62867477 · Jun 27, 2019
Provisional Application 62698459 · Jul 16, 2018
Related Publication 20230172172A1 · Jun 8, 2023
References Cited (119)
US 6586251B2 · Economides et al. · 2003 [cited by applicant]
US 7294754B2 · Poueymirou et al. · 2007 [cited by applicant]
US 7576259B2 · Poueymirou et al. · 2009 [cited by applicant]
US 7659442B2 · Poueymirou et al. · 2010 [cited by applicant]
US 11589562B2 · Murphy · 2023 [cited by examiner]
US 20080078000A1 · Poueymirou et al. · 2008 [cited by applicant]
US 20110200982A1 · Stevens et al. · 2011 [cited by applicant]
US 20130042330A1 · Murphy et al. · 2013 [cited by applicant]
US 20130111616A1 · Macdonald et al. · 2013 [cited by applicant]
US 20130111617A1 · Macdonald et al. · 2013 [cited by applicant]
US 20130117873A1 · Wang et al. · 2013 [cited by applicant]
US 20130340104A1 · Murphy · 2013 [cited by applicant]
US 20140134662A1 · Flavell et al. · 2014 [cited by applicant]
US 20140235933A1 · Lee et al. · 2014 [cited by applicant]
US 20140245466A1 · Macdonald et al. · 2014 [cited by applicant]
US 20140245467A1 · Macdonald et al. · 2014 [cited by applicant]
US 20140310828A1 · Lee et al. · 2014 [cited by applicant]
US 20150089678A1 · Murphy et al. · 2015 [cited by applicant]
US 20150106961A1 · Rojas et al. · 2015 [cited by applicant]
US 20150143558A1 · McWhirter et al. · 2015 [cited by applicant]
US 20150143559A1 · McWhirter et al. · 2015 [cited by applicant]
US 20150208622A1 · Flavell et al. · 2015 [cited by applicant]
US 20150282463A1 · Murphy et al. · 2015 [cited by applicant]
US 20150313194A1 · Hu et al. · 2015 [cited by applicant]
US 20150320021A1 · Wang et al. · 2015 [cited by applicant]
US 20150327524A1 · Murphy et al. · 2015 [cited by applicant]
US 20150342163A1 · Voronina et al. · 2015 [cited by applicant]
US 20150366174A1 · Burova et al. · 2015 [cited by applicant]
US 20160157469A1 · Burova et al. · 2016 [cited by applicant]
US 20160295844A1 · Herndler-Brandstetter et al. · 2016 [cited by applicant]
US 20160345549A1 · Gurer et al. · 2016 [cited by applicant]
US 20170142943A1 · Mujica et al. · 2017 [cited by applicant]
US 20170164588A1 · Olson et al. · 2017 [cited by applicant]
US 20170245481A1 · Gusarova et al. · 2017 [cited by applicant]
US 20170245482A1 · Purcell et al. · 2017 [cited by applicant]
US 20180139940A1 · Macdonald et al. · 2018 [cited by applicant]
US 20180243450A1 · Devalaraja-Narashimha et al. · 2018 [cited by applicant]
US 20190098879A1 · Drummond-Samuelson et al. · 2019 [cited by applicant]
US 20190159436A1 · Mujica et al. · 2019 [cited by applicant]
US 20190290783A1 · Voronina et al. · 2019 [cited by applicant]
US 20200015462A1 · Murphy et al. · 2020 [cited by applicant]
CN 101031316A · 2007 [cited by applicant]
CN 101522716A · 2009 [cited by applicant]
CN 104080808A · 2014 [cited by applicant]
CN 104784688A · 2015 [cited by applicant]
CN 112638154B · 2021 [cited by applicant]
RU 2425880C2 · 2011 [cited by applicant]
WO 2013063556A1 · 2013 [cited by applicant]
WO 2013074569A1 · 2013 [cited by applicant]
WO 2014039782A2 · 2014 [cited by applicant]
WO 2015171861A1 · 2015 [cited by applicant]
WO 2016085889A1 · 2016 [cited by applicant]
WO 2016164492A2 · 2016 [cited by applicant]
WO 2016168542A1 · 2016 [cited by applicant]
Chinese Office Action dated Jul. 22, 2024 received in Chinese Patent Application No. 202211224751.2, together with an English-language translation. [cited by applicant]
Russian Office Action & Search Report dated Oct. 3, 2022 received in Russian Application No. 2020135272/10(064988), together with an English-language translation. [cited by applicant]
European Communication dated Apr. 28, 2022 received in European Application No. 19 749 891.8. [cited by applicant]
Chinese Office Action dated Mar. 3, 2022 received in Chinese Application No. 201980040953.1, together with an English-language translation. [cited by applicant]
International Search Report and Written Opinion dated Sep. 27, 2019 received in International Application No. PCT/US2019/041964. [cited by applicant]
NCBI Reference Sequence No. NP_062323.1 (3 pages) (Jun. 2, 2019). [cited by applicant]
NCBI Reference Sequence No. NP_001100024.1 (2 pages) (May 28, 2018). [cited by applicant]
NCBI Reference Sequence No. NP_055253.2 (3 pages) (Jun. 30, 2019). [cited by applicant]
NCBI Reference Sequence No. NP_081439.1 (3 pages) (Jun. 4, 2019). [cited by applicant]
NCBI Reference Sequence No. NP_003845.2 (4 pages) (Sep. 27, 2019). [cited by applicant]
NCBI Reference Sequence No. NP_598259.1 (3 pages) (Sep. 21, 2019). [cited by applicant]
NCBI Reference Sequence No. NP_062564.1 (3 pages) (Aug. 27, 2019). [cited by applicant]
NCBI Reference Sequence No. NP_001107262.1 (2 pages) (May 28, 2018). [cited by applicant]
NCBI Reference Sequence No. XP_006233676.1 (2 pages) (Jul. 26, 2016). [cited by applicant]
UniProtKB/Swiss-Prot No. Q8R460.1 (3 pages) (Sep. 18, 2019). [cited by applicant]
Bissonnette R. et al., “Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis are Highly Related Diseases that Appear to be Distinct from Psoriasis Vulgaris”, PLoS … [cited by applicant]
Boutet M-A et al., “Distinct Expression of Interleukin (IL)-36α, β and ?, Their Antagonist IL-36Ra and IL-38 in Psoriasis, Rheumatoid Arthritis and Crohn's Disease”, Clinical & Experimental Immunology 184:159-173 (2016). [cited by applicant]
Chen H. et al., “Alterations of Plasma Inflammatory Biomarkers in the Healthy and Chronic Obstructive Pulmonary Disease Patients With or Without Acute Exacerbation”, Journal of Proteomics 75:2835-2843 (2012). [cited by applicant]
Cowen E.W. et al., “DIRA, DITRA, and New Insights into Pathways of Skin Inflammation: What's in a Name?”, Arch Dermatol. 148(3):381-384 (Mar. 2012). [cited by applicant]
D'Erme A M et al., “IL-36y (IL-1F9) is a Biomarker for Psoriasis Skin Lesions”, Journal of Investigative Dermatology 135:1025-1032 (2015). [cited by applicant]
Dennis, Jr. M.B., “Welfare Issues of Genetically Modified Animals”, ILAR Journal 43(2):100-109 (2002). [cited by applicant]
Frey S. et al., “The Novel Cytokine Interleukin-36α is Expressed in Psoriatic and Rheumatoid Arthritis Synovium”, Ann Rheum Dis 72:1569-1574 (2013). [cited by applicant]
Garlanda C. et al., “The Interleukin-1 Family: Back to the Future”, Immunity 39:1003-1018 (Dec. 12, 2013). [cited by applicant]
Glick B. et al., Moleculyarnaya Biotehnologiya. Printsipy i primeneniye. Moscow: Mir, 2002, together with an English-language translation. [cited by applicant]
Harari D. et al., “Bridging the Species Divide: Transgenic Mice Humanized for Type-I Interferon Response”, PLoS One 9(1):1-12 (Jan. 2014). [cited by applicant]
Harusato A. et al., “IL-36y Signaling Controls the Induced Regulatory T Cell-Th9 Cell Balance Via NFκB Activation and STAT Transcription Factors”, Mucosal Immunology 10:1455-1467 (2017). [cited by applicant]
Heller F. et al., “Oxazolone Colitis, a Th2 Colitis Model Resembling Ulcerative Colitis, is Mediated by IL-13-Producing NK-T Cells”, Immunity 17:629-638 (Nov. 2002). [cited by applicant]
Johnston A. et al., “IL-1 and IL-36 are Dominant Cytokines in Generalized Pustular Psoriasis”, J Allergy Clin Immunol 140(1):109-120 (Jul. 2017). [cited by applicant]
Mahil S.K. et al., “An Analysis of IL-36 Signature Genes and Individuals with IL1RL2 Knockout Mutations Validates IL-36 as a Psoriasis Therapeutic Target”, Sci. Transl. Med. 9:1-11 (Oct. 11, 2017). [cited by applicant]
Marrakchi S. et al., “Interleukin-36-Receptor Antagonist Deficiency and Generalized Pustular Psoriasis”, The New England Journal of Medicine 365(7):620-628 (Aug. 18, 2011). [cited by applicant]
Medina-Contreras O. et al., “Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage”, The Journal of Immunology 196:34-38 (2016). [cited by applicant]
Nishida A. et al., “Increased Expression of Interleukin-365, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease”, Inflamm Bowel Dis 22(2):303-314 (Feb. 2016). [cited by applicant]
Okayasu I. et al., “A Novel Method in the Induction of Reliable Experimental Actue and Chronic Ulcerative Colitis in Mice”, Gastroenterology 98(3):694-702 (1990). [cited by applicant]
Onoufriadis A. et al., “Mutations in IL36RN/IL1F5 are Associated With the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis”, The American Journal of Human Genetics 89:432-437 (Sep. 9, 20… [cited by applicant]
Paller A.S. et al., “An IL-17-Dominant Immune Profile is Shared Across the Major Orphan Forms of Ichthyosis”, J Allergy Clin Immunol 139:152-165 (2017). [cited by applicant]
Poueymirou W T et al., “F0 Generation Mice Fully Derived from Gene-Targeted Embryonic Stem Cells Allowing Immediate Phenotypic Analyses”, Nature Biotechnology 25(1):91-99 (Jan. 2007). [cited by applicant]
Rakoff-Nahoum S. et al., “Recognition of Commensal Microflora by Toll-Like Receptors is Required for Intestinal Homeostatis”, Cell 118:229-241 (Jul. 23, 2004). [cited by applicant]
Russell SE et al., “IL-36α Expression is Elevated in Ulcerative Colitis and Promotes Colonic Inflammation”, Mucosal Immunology 9(5):1193-1204 (Sep. 2016). [cited by applicant]
Shaik Y. et al., “IL-36 Receptor Antagonist With Special Emphasis on IL-38”, International Journal of Immunopathology and Pharmacology 26(1):27-36 (2013). [cited by applicant]
Shibata A. et al., “Toll-Like Receptor 4 Antagonist TAK-242 Inhibits Autoinflammatory Symptoms in DITRA”, Journal of Autoimmunity 80:28-38 (2017). [cited by applicant]
Swindell et al., “Genome-Wide Expression Profiling of Five Mouse Models Identifies Similarities and Differences With Human Psoriasis”, PLoS One 6(4):e18266 (Apr. 2011). [cited by applicant]
Thorsvik S. et al., “Fecal Neurophil Gelatinase-Associated Lipocalin as a Biomarker for Inflammatory Bowel Disease”, Journal of Gastroenterology and Hepatology 32: 128-135 (2017). [cited by applicant]
Tong C. et al., “Generating Gene Knockout Rats by Homologous Recombination in Embryonic Stem Cells”, Nat Protoc 6(6):doi:10.1038/nprot.2011.338 (Jun. 2011). [cited by applicant]
Tong C. et al., “Production of p53 Gene Knockout Rats by Homologous Recombination in Embryonic Stem Cells”, Nature 467:211-215 (Sep. 9, 2010). [cited by applicant]
Tortola L. et al., “Psoriasiform Dermatitis is Driven by IL-36-Mediated DC-Keratinocyte Crosstalk”, The Journal of Clinical Investigation 122(11):3965-3976 (Nov. 2012). [cited by applicant]
Towne J.E. et al., “Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal Through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-κB and MAPKs”, The Journal of Biological Chemistry 279(14):13677-13688 (Apr. 2, 200… [cited by applicant]
Towne JE et al., “IL-36 in Psoriasis”, Current Opinion in Pharmacology 12:486-490 (2012). [cited by applicant]
Valenzuela D M et al., “High-Throughput Engineering of the Mouse Genome Coupled With High-Resolution Expression Analysis”, Nature Biotechnology 21(6):652-659 (Jun. 2003). [cited by applicant]
Van Der Fits L. et al., “Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice is Mediated Via the IL-23/IL-17 Axis”, The Journal of Immunology 182:5836-5845 (2009). [cited by applicant]
Zhou L. et al., “Quantitative Ligand and Receptor Binding Studies Reveal the Mechanism of Interleukin-36 (IL-36) Pathway Activation”, Journal of Biological Chemistry 293(2):403-411 (Nov. 27, 2017). [cited by applicant]
Zhou H. et al., “Developing ITA Transgenic Rats for Inducible and Reversible Gene Expression”, International Journal of Biological Sciences 5(2):171-181 (2009). [cited by applicant]
NCBI Reference Sequence No. NM_014440.2 (4 pages) (May 4, 2019). [cited by applicant]
NCBI Reference Sequence No. NM_001106554.1 (2 pages) (May 28, 2018). [cited by applicant]
NCBI Reference Sequence No. NM_019450.3 (4 pages) (Jun. 2, 2019). [cited by applicant]
NCBI Reference Sequence No. NM_014438.4 (4 pages) (May 4, 2019). [cited by applicant]
NCBI Reference Sequence No. NM_001108570.1 (2 pages) (May 28, 2018). [cited by applicant]
NCBI Reference Sequence No. NM_027163.4 (3 pages) (Jun. 4, 2019). [cited by applicant]
NCBI Reference Sequence No. NM_001113790.1 (2 pages) (May 28, 2018). [cited by applicant]
NCBI Reference Sequence No. NM_153511.3 (4 pages) (Sep. 21, 2019). [cited by applicant]
NCBI Reference Sequence No. NM_019618.3 (4 pages) (Oct. 28, 2018). [cited by applicant]
NCBI Reference Sequence No. NM_133575.1 (4 pages) (Sep. 21, 2019). [cited by applicant]
NCBI Reference Sequence No. NM_133193.4 (6 pages) (Feb. 27, 2019). [cited by applicant]
NCBI Reference Sequence No. NM_003854.3 (5 pages) (Jul. 1, 2018). [cited by applicant]
NCBI Reference Sequence No. NP_055255.1 (3 pages) (Sep. 27, 2019). [cited by applicant]
NCBI Reference Sequence No. NP_573456.1 (4 pages) (Feb. 27, 2019). [cited by applicant]